

Ref. No: 2156
Date: 10/11/25
Subject: Hemophilia A patient numbers

REQUEST

- Please provide Hemophilia A patient numbers broken down by: age, disease severity and treatment regimen (PPx denotes use for prophylaxis and OD denotes use on demand). I have proposed a format below to capture the relevant information. If data is not available by age breakdown, then please provide aggregated total in the yellow highlighted column:

July through September 2025	Age											
Brand name (scientific)	0-12 years						13+					
	Mild		Modera te		Severe		Mild		Modera te		Severe	
	PP x	O D	PP x	O D	PP x	O D	PP x	O D	PP x	O D	PP x	O D
Hemlibra (emicizumab)												
Altuvect (giiroctocogene fitelparvovec)												
Esperoct (turoctocog alfa pegol)												
Elocta (efmoroctocog alfa)												
Advate (octocog alfa)												
Kovaltry (octocog alfa)												
Iblias (octocog alfa)												

Refacto AF (moroctocog alfa)													
Xyntha (moroctocog alfa)													
NovoEight (turoctocog alfa)													
Nuwiq (simoctocog alfa)													
Vihuma (simoctocog alfa)													

Inhibitor patients

2. For Hemlibra-treated **Hemophilia A Inhibitor** patients, please indicate the number of patients by age group and dosing frequency for Q3'25 (July–September 2025). If data is not available by age breakdown then please provide aggregated total:

Age group (Hemophilia A inhibitor patients)	Once weekly	Every 2 weeks	Every 4 weeks
0-12 years			
13+ years			
Total			

Non-inhibitor patients

3. For Hemlibra-treated **Hemophilia A non-inhibitor** patients, please indicate the number of patients by age group and dosing frequency for Q3'25 (July–September 2025). If data is not available by age breakdown then please provide aggregated total:

Age group (Hemophilia A non-inhibitor patients)	Once weekly	Every 2 weeks	Every 4 weeks
0-12 years			
13+ years			
Total			

RESPONSE

MWL is not a Haemophilia Comprehensive Care Centre.